The MenB vaccine protects against meningococcal group B bacteria, helping prevent life-threatening meningitis and bloodstream infections in babies, teenagers, and young adults.
The UK’s vaccine advisers have recommended that all teenagers should routinely receive the meningitis B (MenB) vaccine, following a series of deadly outbreaks that claimed several young lives and raised concerns about gaps in protection among adolescents. ()
The recommendation, issued by the Joint Committee on Vaccination and Immunisation (JCVI), calls for the MenB vaccine to become part of the routine adolescent immunization schedule. If accepted by the government, the programme would protect teenagers at an age when they face an increased risk of contracting the life-threatening bacterial infection.
Advertisement
Why Are Experts Calling for Routine MenB Vaccination?
The recommendation comes after several meningitis B outbreaks across England this year, including a major outbreak in Kent that resulted in two deaths and more than a dozen hospitalizations. Separate cases in Berkshire and other areas also resulted in fatalities, prompting renewed scrutiny of the UK’s vaccination strategy.
Following the Kent outbreak, the then Health Secretary Wes Streeting asked the JCVI to review whether teenagers should routinely receive protection against meningococcal group B disease. After reviewing the available evidence, the committee concluded that expanding vaccination would help prevent future outbreaks and reduce the number of severe infections among adolescents and young adults.
Advertisement
Who Would Be Eligible for MenB Vaccine?
The JCVI has proposed a phased approach. Teenagers who received the MenB vaccine as babies under the childhood immunization programme introduced in 2015 would receive a booster dose at around 15 years of age.
Those born before May 2015, who were never routinely offered the infant vaccine, would instead receive two doses during adolescence. The committee also recommended catch-up vaccination for young people who might otherwise miss both programmes. The UK government is now considering the recommendations before deciding whether to implement them nationwide.
Advertisement
What Is Meningitis B?
Meningitis B is caused by the bacterium Neisseria meningitidis serogroup B. It can lead to meningitis—an infection of the protective membranes surrounding the brain and spinal cord—or bloodstream infection (septicemia), both of which can become fatal within hours if left untreated.
Although uncommon, the disease progresses rapidly and remains one of the leading causes of bacterial meningitis in children and young adults.
Early symptoms often resemble flu and may include fever, headache, vomiting, muscle aches, cold hands and feet, drowsiness, confusion, and sensitivity to light. As the illness progresses, patients may develop neck stiffness, seizures, difficulty waking, or the distinctive non-blanching rash associated with meningococcal disease.
Why Are Teenagers at Higher Risk?
Health experts say adolescents and young adults are particularly vulnerable because the bacteria spread through close and prolonged contact, including kissing, sharing drinks or vapes, coughing, and living in shared accommodation.
The risk rises significantly when young people begin university, where communal living and increased social interaction make transmission easier.
According to Meningitis Now, students entering university are among the groups most likely to benefit from vaccination because immunity gained from infancy does not last into adolescence, leaving many teenagers unprotected just as their risk begins to increase.
The charity has long advocated extending MenB vaccination beyond infancy to protect older children and young adults. The MenB vaccine programme for young people also aims to reduce the risk of outbreaks in universities and other residential education settings.
Current Vaccination Programme
Since 2015, the MenB vaccine has been routinely offered to babies in the UK as part of the childhood immunization schedule. However, children born before the programme began generally did not receive the vaccine, creating a gap in protection among today’s teenagers and young adults.
In response to this year’s outbreaks, England has already launched a temporary vaccination campaign for eligible students entering university and other residential education settings, offering free MenB vaccination ahead of the autumn term.
Why the Recommendation Matters
Patient organizations have welcomed the JCVI’s recommendation, saying it could prevent future tragedies by protecting young people before they enter higher-risk environments such as colleges and universities.
While the advice does not automatically change NHS policy, experts say adopting routine adolescent MenB vaccination would significantly strengthen the UK’s protection against one of the fastest-progressing bacterial infections.
The government is expected to review the JCVI’s recommendations before making a final decision on whether the vaccine will become part of the routine NHS immunization schedule.
References:
- MenB vaccine programme for young people – (https://www.meningitisnow.org/meningitis-explained/meningitis-vaccines/menb-vaccine-programme-for-young-people/)
Source-Medindia